EPS details EPS came in at -$0.12. The six earnings estimates compiled by S&P Capital IQ anticipated $0.03 per share. Non-GAAP EPS were -$0.12 for Q1 compared to -$0.04 per share for the prior-year quarter. GAAP EPS were -$0.17 for Q1 versus -$0.04 per share for the prior-year quarter.

Looking ahead Next quarter's average estimate for revenue is $92.2 million. On the bottom line, the average EPS estimate is $0.10.

Next year's average estimate for revenue is $377.3 million. The average EPS estimate is $0.31.

Investor sentiment The stock has a two-star rating (out of five) at Motley Fool CAPS, with 135 members out of 189 rating the stock outperform, and 54 members rating it underperform. Among 53 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 30 give Auxilium Pharmaceuticals a green thumbs-up, and 23 give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Auxilium Pharmaceuticals is outperform, with an average price target of $21.80.

Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment icon found on every comment.